천식 치료제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Asthma Therapeutics Market size is expected to reach USD 53.91 Billion in 2034 from USD 34.84 Billion (2025) growing at a CAGR of 4.97% during 2026-2034.

The asthma therapeutics market is experiencing substantial growth, driven by the increasing prevalence of asthma and the rising demand for effective treatment options. As awareness of asthma management improves, healthcare providers are focusing on personalized treatment plans that address the unique needs of each patient. Innovations in asthma therapeutics, including biologics and targeted therapies, are transforming the landscape of asthma management, offering new hope for patients with severe and uncontrolled asthma. These advancements are complemented by the development of smart inhalers and digital health solutions that enhance medication adherence and monitoring.

Moreover, the growing emphasis on preventive care and early intervention is influencing the asthma therapeutics market. As healthcare systems prioritize proactive management strategies, the demand for effective asthma medications is surging. Additionally, the increasing focus on patient education and self-management is empowering individuals to take control of their asthma, leading to improved outcomes and reduced healthcare costs.

Furthermore, the rise of telemedicine and remote monitoring technologies is facilitating better asthma management. Patients can now access healthcare professionals for consultations and follow-ups without the need for in-person visits, making it easier to manage their condition. This trend is particularly relevant in the context of the COVID-19 pandemic, where remote care has become essential. In conclusion, the asthma therapeutics market is set for robust growth, characterized by innovation, a focus on personalized care, and a commitment to improving the quality of life for asthma patients.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

• Combination Therapies (ICS/LABAs)
• Long-Acting Beta Agonists (LABAs)
• Short-Acting Beta Agonists (SABAs)
• Inhaled Corticosteroids (ICS)
• Oral And Intravenous Corticosteroids
• Leukotriene Modifiers
• Other

By Treatment Type

• Long-Term Asthma Control Medications
• Quick-Relief (Rescue) Medications

By Route Of Administration

• Topical
• Oral
• Injectables

By Distribution Channel

• Brick & Mortar
• Hospital Pharmacies
• E-Commerce

By End-Use

• Hospitals & Clinics
• Ambulatory Surgical Centers
• Homecare Settings

COMPANIES PROFILED

• AstraZeneca, Boehringer Ingelheim, Cipla Ltd, Covis Pharma, GSK plc, Merck Co Inc, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals Inc, Sanofi, Teva Pharmaceutical Industries Ltd

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ASTHMA THERAPEUTICS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. Combination Therapies (ICS/LABAs) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Long-Acting Beta Agonists (LABAs) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Short-Acting Beta Agonists (SABAs) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Inhaled Corticosteroids (ICS) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Oral And Intravenous Corticosteroids Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Leukotriene Modifiers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ASTHMA THERAPEUTICS MARKET: BY TREATMENT TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Treatment Type
• 5.2. Long-Term Asthma Control Medications Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Quick-Relief (Rescue) Medications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ASTHMA THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Topical Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Injectables Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ASTHMA THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Brick & Mortar Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. E-Commerce Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ASTHMA THERAPEUTICS MARKET: BY END-USE 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast End-use
• 8.2. Hospitals & Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Ambulatory Surgical Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Homecare Settings Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL ASTHMA THERAPEUTICS MARKET: BY REGION 2022-2034(USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Drug Class
  • 9.2.2 By Treatment Type
  • 9.2.3 By Route Of Administration
  • 9.2.4 By Distribution Channel
  • 9.2.5 By End-use
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Drug Class
  • 9.3.2 By Treatment Type
  • 9.3.3 By Route Of Administration
  • 9.3.4 By Distribution Channel
  • 9.3.5 By End-use
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Drug Class
  • 9.4.2 By Treatment Type
  • 9.4.3 By Route Of Administration
  • 9.4.4 By Distribution Channel
  • 9.4.5 By End-use
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Drug Class
  • 9.5.2 By Treatment Type
  • 9.5.3 By Route Of Administration
  • 9.5.4 By Distribution Channel
  • 9.5.5 By End-use
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 South East Asia
  • 9.5.11 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Drug Class
  • 9.6.2 By Treatment Type
  • 9.6.3 By Route Of Administration
  • 9.6.4 By Distribution Channel
  • 9.6.5 By End-use
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL ASTHMA THERAPEUTICS INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 AstraZeneca
  • 11.2.2 Boehringer Ingelheim
  • 11.2.3 Cipla Ltd
  • 11.2.4 Covis Pharma
  • 11.2.5 GSK Plc
  • 11.2.6 Merck & Co. Inc
  • 11.2.7 Novartis Pharmaceuticals Corporation
  • 11.2.8 Regeneron Pharmaceuticals Inc
  • 11.2.9 Sanofi
  • 11.2.10 Teva Pharmaceutical Industries Ltd